When Will Mounjaro Be Available on the NHS — and What's Already Changed

You checked the NICE guidance and thought you qualified, here's why it's still complicated

You've probably done the maths. NICE published its recommendation for tirzepatide in December 2024 (NICE technology appraisal TA1026) and it looked promising. The catch is that a NICE recommendation and actual NHS availability are two different things. NHS England translates NICE recommendations into a commissioning process, and for Mounjaro that process is deliberately staged rather than opened all at once.

The first group became eligible from June 2025: adults with a BMI of 40 or above and four or more of a defined set of weight-related conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes). If you have three of those conditions, or a lower BMI, you're not in this cohort. That's not a reflection of need; it's a capacity decision.

It's worth spending sixty seconds checking your own BMI against the NHS calculator at nhs.uk before your next GP appointment, knowing your number precisely avoids an avoidable conversation about whether you're borderline. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, so the same check may read differently depending on which guidance your GP is using.

Even within the eligible cohort, GP participation is optional under the 2026/27 QOF contract, and every NHS patient must be enrolled in wraparound lifestyle support. In practice, that means availability varies considerably from one practice to another. For a fuller picture of what 'available on the NHS' actually means today, it's a more nuanced answer than headlines suggest.

When the next cohorts open, the timetable NHS England has set out

NHS England's phased plan means more people will become eligible over time, but the timeline runs to at least 2027. Cohort 2 (adults with a BMI of 35 to 39.9 and four or more of the same qualifying conditions) opened in June 2026. Cohort 3, covering BMI of 40 or above with three qualifying conditions, is expected from around March 2027.

If you're trying to work out when Mounjaro will be available on prescription for someone with your profile specifically, the honest answer depends on your BMI and how many of those five conditions appear in your clinical record. The NHS eligibility criteria for tirzepatide page sets out each cohort in detail, including the ethnic-background adjustments.

There is no current NHS pathway for adults with a BMI below 35 who don't have multiple comorbidities, and no confirmed date for one. The phased approach reflects both budget constraints and the practical capacity of weight management services. If you're in Wales, Scotland or Northern Ireland, the position differs, devolved health services set their own access criteria, and Scotland in particular uses different thresholds. A note about Mounjaro access in Wales covers the devolved picture there.

One thing that won't change: whichever NHS cohort eventually opens to you, it will require a clinical assessment. No stage of the rollout bypasses a prescriber's judgment.

What people who don't want to wait are doing instead

Private prescription is the legal route for people who are clinically suitable but fall outside the current NHS cohorts, or who are inside them but facing long waits. This matters because tirzepatide is a prescription-only medicine; there is no over-the-counter version, and obtaining it without a valid prescription is both unsafe and unlawful.

The private route works through a GPhC-registered pharmacy. A prescriber reviews your consultation, at nume, that's a named GPhC-registered Independent Prescriber reading your answers directly, not an algorithm processing them. If you're approved, treatment is dispatched the same day for orders placed before noon, arriving via tracked DPD delivery the following working day. If you'd like to understand how the private prescription process works in practice, the steps are straightforward.

Cost is a fair question. Mounjaro's UK list price rose significantly from September 2025 following a price change by Eli Lilly, and private prices now typically range from roughly £149 to £375 per month depending on dose and provider. A transparent picture of what Mounjaro costs privately is worth reading before you decide. One thing to be clear-eyed about: a lower private price is not automatically better. For a prescription medicine supplied through a regulated clinical pathway, the question of whether the pharmacy is GPhC-registered matters more than whether you're paying £20 less per pen. You can verify any online pharmacy in under a minute at the GPhC register, it's the strongest reassurance that a UK pharmacy is operating legally.

If the NHS timetable shifts, or if you become eligible for a later cohort, nothing about having used a private prescription locks you out of NHS treatment in the future. The two routes are independent. Ready to see whether you're clinically suitable for private treatment now? Check your eligibility with our prescribers, the consultation is free, and there's no obligation.